Savara (SVRA) Preferred Dividend Payments (2016 - 2017)
Savara (SVRA) reported Preferred Dividend Payments of $554000.0 for Q2 2017, up 27600.0% year-over-year from N/an in Q2 2016, and up 2208.33% on a QoQ basis from $24000.0 in Q1 2017.
Savara (SVRA) has 2 years of Preferred Dividend Payments data on file, last reported at $554000.0 in Q2 2017.
- Quarterly Preferred Dividend Payments rose 27600.0% year-over-year to $554000.0 in Q2 2017, while the trailing twelve-month figure through Dec 2017 was $578000.0 (changed N/A YoY) and the FY2017 annual result came in at $578000.0, up 514.89% from the prior year.
- Preferred Dividend Payments improved to $554000.0 in Q2 2017 per SVRA's latest filing, from $24000.0 in the prior quarter.
- Across five years, Preferred Dividend Payments topped out at $554000.0 in Q2 2017 and bottomed at $2000.0 in Q2 2016.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Pref Dividends (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Savara | 1.30 Bn | 1.30 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2017 | 554,000.00 |
| Mar 31, 2017 | 24,000.00 |
| Dec 31, 2016 | 24,000.00 |
| Sep 30, 2016 | 44,000.00 |
| Jun 30, 2016 | 2,000.00 |